AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70% ... The anti-inflammatory injection, also known as adalimumab, lost its U.S ...

For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulation of Humira ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

Yesterday, Amgen announced that it would launch the U.S.’s first marketed Humira-referenced biosimilar, Amjevita (adalimumab-atto), at two different list prices: $3,288 and $1,557 per 40 mg pen ...

AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition. Humira still dominated 96% of ...